C. -J. Soussy, J. Nguyen, F. Goldstein, H. Dabernat, A. Andremont, R

Slides:



Advertisements
Similar presentations
Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages
Advertisements

Laboratory diagnosis and biosafety issues of biological warfare agents
K. Kümmerer, A. Henninger  Clinical Microbiology and Infection 
Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times  F.B. Spencker, L. Staber, T. Lietz,
Interpretive criteria of ceftibuten disk diffusion susceptibility tests according to the DIN method  Kleinkauf N. , Rodloff A.C.   Clinical Microbiology.
Approach to diagnosis of infective endocarditis
Molecular characterization of methicillin-resistant Staphylococcus aureus isolated over a 2-year period in a Qatari hospital from multinational patients 
A new method for normalized interpretation of antimicrobial resistance from disk test results for comparative purposes  G. Kronvall, G. Kahlmeter, E.
P. Clarke, S. Murchan, E.G. Smyth, H. Humphreys 
Herpes zoster in non-hospitalized children
In vitro activity of several antimicrobial peptides against colistin-susceptible and colistin- resistant Acinetobacter baumannii  X. Vila-Farres, C. Garcia.
K. Kümmerer, A. Henninger  Clinical Microbiology and Infection 
In vitro effects of cefotaxime and ceftriaxone on Salmonella typhi within human monocyte-derived macrophages  B. Ekinci, A.Y. Coban, A. Birinci, B. Durupinar,
In-vitro susceptibility and molecular characterisation of macrolide resistance mechanisms among Streptococcus pneumonia isolates in The Netherlands: the.
A new method for normalized interpretation of antimicrobial resistance from disk test results for comparative purposes  G. Kronvall, G. Kahlmeter, E.
Trends in quinolone susceptibility of Enterobacteriaceae among inpatients of a large university hospital: 1992–98  J. Robert, E. Cambau, K. Grenet, D.
Louis Pasteur, from crystals of life to vaccination
How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development  R. Bax  Clinical Microbiology.
Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY Antimicrobial Surveillance Program  M.
Revision of linezolid disk diffusion quality control guidelines for testing Staphylococcus aureus ATCC 25923: an independent seven-laboratory trial  D.J.
AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on.
C.G. Giske, C. Borén, B. Wretlind, G. Kronvall 
W. Witte, B. Pasemann, C. Cuny  Clinical Microbiology and Infection 
In vitro activity, postantibiotic effect and human monocyte activity of grepafloxacin against Legionella species  Jacques Dubois, Claude St-Pierre  Clinical.
The role of fourth-generation cephalosporins in the treatment of infections caused by penicillin-resistant streptococci  Keith Klugman, Fred Goldstein,
Sofie Arens, Jan Verhaegen, Ludo Verbist 
Multicenter study of the in vitro activity of cefepime in comparison with five other broad- spectrum antibiotics against clinical isolates of Gram-positive.
Training for the infectious diseases speciality in Norway
Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals  C. Nonhoff, O. Denis,
Laboratory diagnosis and biosafety issues of biological warfare agents
Comparative in vitro activity of ertapenem against bacterial pathogens isolated from patients with lower respiratory tract infections  P.S. Hicks, B.
False synergy between vancomycin and β-lactams against glycopeptide-intermediate Staphylococcus aureus (GISA) caused by inappropriate testing methods 
G. Kronvall  Clinical Microbiology and Infection 
S. Bengtsson, C. Bjelkenbrant, G. Kahlmeter 
In vitro selection of antibiotic resistance in Pseudomonas aeruginosa
Antimicrobial susceptibility in Escherichia coli of human and avian origin—a comparison of wild-type distributions  M. Sjölund, S. Bengtsson, J. Bonnedahl,
Isolation rate, T-serotyping and susceptibility to antibiotics of Group A Streptococcus from pediatric infections in Athens*   M. Kanellopoulou, A. Makri,
L. Arreaza, J.A. Vázquez  Clinical Microbiology and Infection 
MIC distribution and inoculum effect of LY333328: a study of vancomycin-susceptible and VanA-type and VanC-type enterococci obtained from intensive care.
Laboratory diagnosis of Clostridium difficile disease
N. Maggi-Solcà, C. Valsangiacomo, J.-C. Piffaretti 
Jacques Sirot, Patrice Courvalin, Claude-James Soussy 
A. Bryskier  Clinical Microbiology and Infection 
Pathogenesis of catheter-related infections: lessons for new designs
J. Garau  Clinical Microbiology and Infection 
Single- and multistep selection study of the antipneumococcal activity of BMS compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin 
Harmonised monitoring of antimicrobial resistance in Salmonella and Campylobacter isolates from food animals in the European Union  S. Bronzwaer  Clinical.
Comparative antimicrobial spectrum and activity of the desfluoroquinolone BMS (T-3811) tested against non-fermentative Gram-negative bacilli  W.
C. Oprica, C.E. Nord  Clinical Microbiology and Infection 
A.P. Underwood, J. Green  Clinical Microbiology and Infection 
Definition of the Clinical Antibacterial Spectrum of Activity
Clinical Microbiology and Infection
W. Eugene Sanders, Christine C. Sanders 
Evaluation of the performance of the Helico Blot 2
Evaluation of the CLSI cefoxitin 30-µg disk-diffusion method for detecting methicillin resistance in staphylococci  L.-X. Zhu, Z.-W. Zhang, C. Wang, H.-W.
The in vitro activity of moxifloxacin against Haemophilus influenzae and Moraxella catarrhalis explored using a pharmacodynamic model  Alasdair P. MacGowan,
Calibration of the disk diffusion test for trovafloxacin susceptibility testing of four anaerobic species  G. Kronvall, E. Holst  Clinical Microbiology.
K. Kaier, N.T. Mutters, U. Frank  Clinical Microbiology and Infection 
Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe  Robert D. Fox  Clinical Microbiology.
Abstracts Clinical Microbiology and Infection
In vitro activity of evernimicin and selected antibiotics against methicillin-resistant staphylococci: a 24-country study  R. Goering, C.-E. Nord, R.
Modification of prescribers’ behavior: the Icelandic approach
In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species†   C.B. Moore,
Are we losing the fight against malaria one more time?
Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group†   H. Goossens  Clinical.
G.C. Schito  Clinical Microbiology and Infection 
The DUEL study: a multi-center in vitro evaluation of linezolid compared with other antibiotics in the Netherlands  J.W. Mouton, A.R. Jansz  Clinical.
AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on.
Activity of linezolid against Gram-positive cocci isolated in French hospitals as determined by three in-vitro susceptibility testing methods  C. Muller-Serieys,
Fernando Baquero, John F
Presentation transcript:

In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study  C.-J. Soussy, J. Nguyen, F. Goldstein, H. Dabernat, A. Andremont, R. Leclercq, H. Drugeon, P. Cavallo, H. Chardon, J. Etienne, Y. Rio, P. Courvalin  Clinical Microbiology and Infection  Volume 9, Issue 10, Pages 997-1005 (October 2003) DOI: 10.1046/j.1469-0691.2003.00696.x Copyright © 2003 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 1 Correlation between the inhibition zone diameters (mm) obtained with a 5-μg moxifloxacin disc (y-axis) and the log2 of the MIC (mg/L) of moxifloxacin determined by agar dilution (x-axis) for 1815 strains. Clinical Microbiology and Infection 2003 9, 997-1005DOI: (10.1046/j.1469-0691.2003.00696.x) Copyright © 2003 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 2 Distribution of the clinical isolates as being susceptible, intermediate, and resistant according to the MICs (S.I.R) and inhibition zone diameters (s.i.r) obtained with 5-μg moxifloxacin disc. Clinical Microbiology and Infection 2003 9, 997-1005DOI: (10.1046/j.1469-0691.2003.00696.x) Copyright © 2003 European Society of Clinical Infectious Diseases Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.